Physician profile
Matthew E Bettag
NPI 1487646675
$399.51
in general payments reported to CMS, 2019-2025
13 companies · $39.03 in 2025
The $39.03 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $24.84 · 2021: $52.24 · 2022: $57.19 · 2023: $80.76 · 2024: $27.11 · 2025: $39.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $92.01 | 2019-2021 | |
| Genzyme Corporation | $54.13 | 2021-2023 | |
| Glaxosmithkline, LLC. | $49.42 | 2021-2023 | Nucala |
| Gilead Sciences, INC. | $37.11 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $29.28 | 2023-2024 | Libtayo |
| Array Biopharma INC | $20.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2019 | |
| Stryker Corporation | $16.59 | 2025 | Scopis Ent |
| Aerin Medical INC. | $15.56 | 2022 | |
| Integra Lifesciences Corporation | $13.39 | 2020 | |
| Celgene Corporation | $13.13 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bettag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.